IGHE and asthma: Given serum IgE levels are tested to guide omalizumab dosing in patients with severe asthma and blood eosinophil count is not required for treatment, this may have resulted in a lower prevalence of blood eosinophil count testing than may be expected if this study was repeated following these more recent approvals.